Evidence map›Paper›PMID 35468986›Full record

ArticleScientific reports2022

Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer.

Camille Barbier, Ali Mansour, Aiten Ismailova, Fatemeh Sarmadi, David A Scarlata, Manuella Bouttier, Camille Zeitouni, Catherine Wang, James L Gleason, John H White

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Camille BarbierDepartments of Physiology, McGill University, Montreal, QC, Canada.
Ali MansourDepartments of Chemistry, McGill University, Montreal, QC, Canada.
Aiten IsmailovaDepartments of Physiology, McGill University, Montreal, QC, Canada.
Fatemeh SarmadiDepartments of Physiology, McGill University, Montreal, QC, Canada.
David A ScarlataDepartments of Chemistry, McGill University, Montreal, QC, Canada.
Manuella BouttierDepartments of Physiology, McGill University, Montreal, QC, Canada.
Camille ZeitouniDepartments of Physiology, McGill University, Montreal, QC, Canada.
Catherine WangDepartments of Physiology, McGill University, Montreal, QC, Canada.
James L GleasonDepartments of Chemistry, McGill University, Montreal, QC, Canada. jim.gleason@mcgill.ca.
John H WhiteDepartments of Physiology, McGill University, Montreal, QC, Canada. john.white@mcgill.ca.
McGill University · CA

Funding

CIHR
6 · The paper itself

Abstract

The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies because they exhibit synergistic activities with other anticancer agents such as histone deacetylase inhibitors (HDACi). We have developed a series of hybrid molecules that combine HDACi within the backbone of a VDR agonist and thus represent fully integrated bifunctional molecules. They exhibit anti-tumor efficacy in reducing tumor growth and metastases in an aggressive model of triple-negative breast cancer. However, their solubility is limited by their hydrophobic diarylpentane cores. Our goals here were two-fold: (1) to improve the solubility of hybrids by introducing nitrogen into diarylpentane cores, and (2) to investigate the molecular mechanisms underlying their anti-tumor efficacy by performing comparative gene expression profiling studies with 1,25D and the potent HDACi suberoylanilide hydroxamic acid (SAHA). We found that substituting aryl with pyrydyl rings did not sacrifice bifunctionality and modestly improved solubility. Notably, one compound, AM-193, displayed enhanced potency as a VDR agonist and in cellular assays of cytotoxicity. RNAseq studies in triple negative breast cancer cells revealed that gene expression profiles of hybrids were very similar to that of 1,25D, as was that observed with 1,25D and SAHA combined. The effects of SAHA alone on gene expression were limited and distinct from those 1,25D or hybrids. The combined results suggest that efficacy of hybrids arises from targeting HDACs that do not have a direct role in gene regulation. Moreover, pathways analysis revealed that hybrids regulate numerous genes controlling immune cell infiltration into tumors and suppress the expression of several secreted molecules that promote breast cancer growth and metastasis.

Indexed as

Antineoplastic AgentsTriple Negative Breast NeoplasmsCell ProliferationHistone Deacetylase InhibitorsHumansReceptors, CalcitriolVorinostatAntineoplastic AgentsHistone Deacetylase InhibitorsReceptors, CalcitriolVorinostat

Identifiers

PMID35468986
PMCPMC9038752
OpenAlexW4224443226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.